Prothena targets rare protein-misfolding disease in late-stage study

Elan Corp. spinout Prothena Corp. will take an experimental drug aimed at a rare protein-misfolding disease into a late-stage clinical trial, the company said Tuesday. Prothena (NASDAQ: PRTA), whose operations are largely based in South San Francisco, said it will focus its drug on amyloid light-chain amyloidosis, or AL amyloidosis, in what's expected to be a 230-patient, Phase III study. In the disease, misfolded amyloid proteins are deposited in tissue, causing progressive organ damage, including…
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Authors: Source Type: news